*Failure to attain remission despite 4 weeks of therapy with daily prednisolone at 60mg/m 2 * Most paediatric nephrologists would give either 6-8 weeks of daily prednisolone 5 at 60mg/m 2 or 4 weeks of daily prednisolone at 60mg/m 2 plus 3 pulses of IV methylprednisolone at 600mg/m 2 given on alternate days 6 prior to considering a patient to be steroid resistant. _________________________________________
(Keywords: Current practice, childhood nephrotic syndrome, management, steroid-sensitive) Nephrotic syndrome (NS), which refers to the tetrad of heavy proteinuria, oedema, hypoalbuminaemia and hyperlipidaemia, is the commonest childhood glomerular disorder and the annual incidence is 2-7 per 100, 000 1 . It can be classified as secondary, congenital and idiopathic, with idiopathic NS being the most common type in children. NS manifests as the primary disease in the majority while in the remainder it is secondary to systemic disorders such systemic lupus erythematosus, vasculitis and infections, or may occur following ingestion of drugs and heavy metals 2 . The majority of children show minimal change nephropathy (MCN) or focal and segmental glomerulosclerosis (FSGS) upon histological examination.
While the majority of children with MCN respond to the initial corticosteroid therapy, over 70% of them will subsequently develop relapses. Around 50% of these will have frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). However, with treatment, most patients will enter long-term remission without progressing to end-stage renal failure 3, 4 . The definitions related to NS are mentioned in table 1. This article will focus on the management of steroid-sensitive nephrotic syndrome (SSNS). Two or more relapses in initial 6 months or more than four relapses in any 12 months Steroid dependence :
Two consecutive relapses when on alternate day steroids or within 14 days of its discontinuation. 
Initial evaluation

Treatment of the initial episode
Specific treatment
After years of intensive research, prednisolone remains the first line agent for treatment of the initial episode. The ideal regimen to treat the initial episode should rapidly induce remission and reduce subsequent relapse rates, while keeping steroidrelated side effects to a minimum. Oral prednisolone, prescribed in a dose of 60mg/m 2 every day for 4 weeks, followed by 40mg/m 2 every other day (EOD) for another 4 weeks, in accordance with the recommendations of the International Study for Kidney Diseases in Children (ISKDC) 7 , remained the standard therapy for around a quarter of a century. More than 80% of children respond to the initial therapy 8 .
However, a somewhat large and abrupt drop in the steroid concentration in the body is caused by the standard regimen when switching from 60mg/m 2 daily to 40mg/m 2 EOD. This significant reduction opens a window for relapses in some patients. Moreover, subsequent published evidence suggests that prolonged tapering of steroids is more effective in maintaining the sustained remission rate than the standard regimen 9,10,11 . It has also been shown that the time taken to attain remission in the first episode has a bearing on future severity of the disease i.e. those taking longer than 10 to 14 days have more severe disease than those attaining remission quickly 12 .
These late responders may benefit from a prolonged course of steroids. We therefore recommend the following treatment for the initial episode.
• Early responder (remission induction within 14 days) Prednisolone 60mg/m 2 every day for 4 weeks, followed by prednisolone 60mg/m 2 EOD for 2 weeks, tapered every 2 weeks over a period of 8-12 weeks. • Late responder (remission induction after 14 days) Prednisolone 60mg/m 2 every day for 6 weeks, followed by prednisolone 60mg/m 2 EOD for 2 weeks tapered every 2 weeks over a period of 18 weeks
Treatment of relapse
The standard therapy for relapse according to the modified ISKDC regimen is prednisolone 60mg/m 2 every day till remission, followed by 40mg/m 2 EOD for 28 days 7 . However, for the same reasons noted above, switching from 60mg/m 2 daily to 60mg/m 2 EOD for 2 weeks and gradually tapering over a variable period of time is more desirable(4-12 weeks). The duration of the taper would be determined by the frequency of relapses and more frequent relapses require a longer duration taper.
Prevention of relapses
Relapse of NS is frequently precipitated by viral upper respiratory tract infection (URTI) 13 . Several studies have demonstrated a reduction in relapse rate by a slight, short term increase in the prednisolone dose at the commencement of an URTI in patients with SDNS who were on EOD corticosteroids 13, 14, 15 . Another study recently demonstrated that a 5 day course of prednisolone prescribed at 0.5mg/kg/day during URTI is capable of reducing the relapse frequency in patients who are off steroids 16 . Based on these findings we make the following recommendations.
At onset of URTI • Patients receiving EOD prednisolone >0.5mg/kg
Give same EOD dose daily for 5-7 days e.g. For a 20kg patient on 15mg EOD, give 15mg daily for 5-7 days • Patients receiving EOD prednisolone <0.5mg/kg Give 0.5mg/kg daily for 5-7 days e.g. For a 20kg patient on 5mg EOD, give 10mg daily for 5-7 days • Patients not receiving prednisolone Give prednisolone 0.5mg/kg daily for 5 days
Steroid dependent and frequently relapsing disease
The first line of treatment for FRNS and SDNS is maintenance therapy with low dose prednisolone 0.1-0.6mg/kg EOD for a period of 6 months followed by slow tapering 7 . In these patients for whom repeated doses of steroids are required, it is necessary to monitor for steroid toxicity with routine check-up of growth and blood pressure 7 .
Steroid-sparing agents such as cyclophosphamide (CYC), cyclosporine A (CyA), levamisole (LEV), mycophenolate mofetil (MMF) and tacrolimus are used if the dose needed to maintain stable remission exceeds 0.6mg/kg EOD or if the child develops steroid toxicity 17 . The following table summarises the treatment regimens with different steroid-sparing agents for SSNS patients. The choice of steroid sparing agent should ideally be made following discussion with a paediatric nephrologist to select the most appropriate agent. The flow chart in Figure 1 is a general guide for selection of steroid-sparing agents.
Although not routinely practised in Sri Lanka, it is advisable to screen for tuberculosis using chest Xray and tuberculin test prior to starting heavy immunosuppressive drugs.
Management of complications of NS Infections
Infections are the main cause of mortality in patients with NS. Cellulitis and other soft tissue infections, peritonitis, urinary tract infection and pneumonia are the most common infections seen in children with NS 18, 19 . Commonly isolated causative agents include S. Pneumonia and Escherichia coli 20 . There is no strong evidence for the use of a prophylactic antibiotic. However, prophylactic penicillin V may be used in the oedematous patient to prevent infection.
Viral infections are also important, with varicella zoster virus being the most significant agent leading to the risk of mortality, especially in children having heavy immunosuppressive therapy 21 . Other important viruses that are likely to trigger relapses include respiratory syncytial virus, influenza virus, parainfluenza virus and adenovirus 22 .
Though difficult to carry out in local clinical settings, it is advisable to immunise all children with NS with pneumococcal, varicella, influenza, MMR and hepatitis B vaccines whenever possible 23 .
Oedema
Oedema, a primary feature of NS, is usually associated with intravascular hypovolaemia and presents with tachycardia, abdominal pain, hypotension and oliguria. Restriction of dietary sodium to <2 mEq/kg per day and fluid restriction can be employed to manage mild oedema, while monitoring body weight. Oral thiazide diuretic therapy can be considered if the eGFR is normal 24 .
If severe oedema presents with the above mentioned symptoms and more than 7-10% increase of body weight, pharmacological interventions with loop diuretics would be required. However, it must be stressed that diuretics should be considered only in euvolaemic patients. As a general rule, if in doubt about volume statusdo not use diuretics. In the suitable patient frusemide can be started at 1-3mg/kg/day and can be increased as necessary up to 4-6mg/kg/day. Due to the pharmacokinetics of frusemide, namely its transport in an albumin bound form, higher doses are usually required for effective diuresis. However, a gradual increase is advisable. Close clinical supervision is needed with electrolyte monitoring and looking for evidence of hypovolaemia. For loop diuretics, intravenous administration is more effective than oral therapy 25 .
There are 3 primary indications for therapy with human albumin in patients with NS in relapse.
1. Hypovolaemic shock 2. Hypovolaemia without shock 3. Refractory or symptomatic oedema Note -A low serum albumin alone is never an indication for intravenous albumin.
Hypovolaemia
usually occurs with the development of oedema. Hypovolaemia and shock can lead to acute renal failure. Injudicious use of diuretics to control oedema is known to precipitate hypovolaemia. Low volume pulse, paradoxical hypertension with narrow pulse pressure, hypotension, cold peripheries and abdominal cramps suggest hypovolaemia and diminished excretion of urinary sodium less that 5mmol/l confirms hypovolaemia and impending shock 12 .
For patients in hypovolaemic shock, 10ml per kg of 4.5% albumin should be infused without diuretics. In patients with hypovolaemia without shock or if the patient has either refractory or symptomatic oedema, 0.5-1g/kg of 20% albumin (2.5-5ml/kg) should be administered over 4-6 hours. Intravenous frusemide should be administered mid-infusion and repeated at the end if diuretic response is poor 26 . Close monitoring should prevail during albumin infusion.
Dyslipidaemia and obesity
The dyslipidaemia seen in NS is usually transient and resolves once the proteinuria clears. It therefore usually does not warrant treatment with lipid lowering agents. Drug therapy can be considered if fasting low-density lipoprotein cholesterol levels are persistently between 160 and 190 mg/dL (4.1-4.9 mmol/L) 27 .
Obesity due to long-term steroid use can be controlled through dietary counselling and exercise. Prolonged corticosteroid therapy can increase the risk of osteoporosis and osteomalacia. Calcium and Vitamin D supplementation might be helpful in managing this condition, although not yet supported by studies.
Hypertension
Persistent hypertension in the normovolaemic patient is unusual in idiopathic NS and warrants consideration of a secondary cause for the NS. This is especially so if the patient continues to be hypertensive once steroids are tapered to lower alternate day doses. There is, however, a higher prevalence of hypertension in NS children with long standing disease 28 and hence prevention of cardiovascular disease through early management is advisable. Dietary changes, exercise and weight management would be helpful. Pharmacological intervention with angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers or beta adrenergic antagonists might be required if blood pressure exceeds the 90 th percentile for age 12 .
Thromboembolic disease
Though NS associated thromboembolic disease (TED) is commoner in adults, TED is the second most frequent cause of death in children with NS. Respiratory compromise is seen in pulmonary embolism while venous thrombosis presents with painful and swollen extremities. Upon suspicion of TED, a computerised tomography pulmonary angiography (CTPA) should be done to confirm the diagnosis. The laboratory tests comprise:
• Platelet count • Prothrombin time • Activated partial thromboplastin time • Thrombin time • Fibrinogen and quantitative D-dimers A child with venous thromboembolism would be given an initial 3-6 months of anticoagulation treatment. If long term anticoagulation is needed, simultaneous warfarin can be started. All patients who have had a thrombotic episode during a relapse should receive anticoagulation with heparin at all subsequent relapses 12 .
